Novocure Ltd
Change company Symbol lookup
Select an option...
NVCR Novocure Ltd
ZSANQ Zosano Pharma Corp
BIPC Brookfield Infrastructure Corp
UTG Reaves Utility Income Trust
ARDLF Ardent Leisure Group Ltd
BFS Saul Centers Inc
ABB Abb Ltd
BURL Burlington Stores Inc
TNEN True North Energy Corp
H Hyatt Hotels Corp
Go

Health Care : Health Care Equipment & Supplies | Mid Cap Growth
Based in Jersey

NovoCure Limited is an oncology company. The Company is principally engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. TTFields therapy is a treatment that uses electric fields tuned to specific frequencies to disrupt cancer cell division. TTFields therapy is delivered through a portable medical device. Optune is approved by the United States Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Optune Lua is approved by the FDA for the pathway for the treatment of malignant pleural mesothelioma (MPM) together with standard chemotherapies. It markets its products to United States, European Union, Germany, Japan and certain other countries.

Closing Price: $79.89

Day's Change: 3.11 (4.05%)

Bid: --

Ask: --

B/A Size: --

Day's High: 80.27

Day's Low: 77.84

Volume (Light) Volume: 395,071 10-day average volume: 614,992: 395,071

Yesterday's News, August 10, 2022
8:00 am ET	Novocure Hosts U.S. Sen. Maggie Hassan at Company's Portsmouth Facility On Tuesday, Aug. 9, U.S. Sen. Maggie Hassan (NH) joined members of Novocure's leadership team to tour the company's U.S. headquarters in Portsmouth, New Hampshire, and learn more about Novocure's groundbreaking work to extend patient survival in...(BusinessWire)
July 28, 2022
7:00 am ET	Novocure Reports Second Quarter 2022 Financial Results Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its...(BusinessWire)
July 27, 2022
8:00 am ET	Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program Novocure today announced the recipients of the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The AACR-Novocure Grants for Tumor Treating Fields Research Program represents a joint effort between Novocure and the...(BusinessWire)
July 01, 2022
8:00 am ET	Novocure to Report Second Quarter 2022 Financial Results Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2022 on Thursday, July 28, 2022, before the U.S. financial markets open. Novocure's management will host a conference call and webcast to discuss...(BusinessWire)
June 21, 2022
8:00 am ET	Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA(R) for Patients with First-Line Stage III Non-Small Cell Lung Cancer Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its phase 2 pilot KEYNOTE-B36 study, conducted in collaboration with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA. KEYNOTE-B36 is designed to evaluate the...(BusinessWire)
June 03, 2022
8:00 am ET	Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer EQNX::TICKER_START (NasdaqGM:ZLAB),(HKSE:9688.HK),(NASDAQ:NVCR), EQNX::TICKER_END Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy (Globe Newswire)
8:00 am ET	Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer --Duration of response was 10.3 months --One-year survival was 72% Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, and Zai Lab (NASDAQ: ZLAB; HKEX: 9688), an innovative...(BusinessWire)
May 26, 2022
8:00 am ET	Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA(R) (pembrolizumab) in Newly Diagnosed Glioblastoma Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, to study the use of Tumor Treating Fields (TTFields) concomitant with MSD's...(BusinessWire)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and